Hickish, Tamas http://orcid.org/0000-0001-6770-7279
Mehta, Ajay
Liu, Mei-Ching
Huang, Chiun-Sheng
Arora, Rajendra Singh
Chang, Yuan-Ching
Yang, Youngsen
Vladimirov, Vladimir
Jain, Minish
Tsang, Janice
Pemberton, Karine
Sadrolhefazi, Behbood
Jin, Xidong
Tseng, Ling-Ming
Funding for this research was provided by:
Boehringer Ingelheim
Article History
Accepted: 11 September 2021
First Online: 9 February 2022
Declarations
:
: M-CL has received travel and accommodation costs and expenses from Pfizer. C-SH has been involved with advisory councils or committees for Roche, Amgen, Eli Lilly, and Pfizer, received honoraria from Roche, Amgen, Eli Lilly, Pfizer, and Novartis, and received grants or funds from AstraZeneca, Daiichi Sankyo, EirGenix, Eli Lilly, MSD, Novartis, OBI Pharma, Pfizer, and Roche. JT has received honoraria from Amgen, NanoString, Novartis, Pfizer, and Roche and has received consulting fees from NanoString and Pfizer. KP, BS and XJ are current employees of Boehringer Ingelheim. TH, AM, RSA, Y-CC, YY, VV, MJ, and L-MT declare no potential conflict of interest.
: Ethical approval was received by the Southampton and West Hampshire Research Ethics Committee (REC). The clinical trial protocol, patient information leaflet, informed consent form, and other locally required documents were received by the Independent Ethics Committees (IECs) and/or Institutional Review Boards (IRBs) of the participating centers prior to study initiation. These IECs and/or IRBs met the requirements of the International Council on Harmonization (ICH) Harmonized Tripartite Guideline for Good Clinical Practice (GCP) and local legislation. The competent authority (Medicines and Healthcare Regulatory Agency, UK) approved the trial on 25th November 2010.
: Not applicable.